Reckitt Capitalizes As COVID Moves From Pandemic To Endemic

Reckitt's OTC sales jumped 60% in the first half of 2022 as the milder omicron COVID-19 variant drove up demand for its leading cold and flu brands. This strong showing has led the firm to raise its full-year group sales guidance from 1-4% to 5-8%.